Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2022 07:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
March 08, 2022 13:59 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer

Ampligen® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at...
March 07, 2022 08:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline

OCALA, Fla., March 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
March 03, 2022 08:35 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer

OCALA, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
January 26, 2022 08:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar

AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm - 3:00 pm ET Company to discuss clinical plans for investigational drug Ampligen for the treatment of myalgic...
January 24, 2022 08:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer

Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and...
January 24, 2022 08:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech宣布发表晚期复发性卵巢癌腹腔内化学免疫疗法1/2期研究的积极结果

趋化因子调节IP化学免疫疗法组合被证明具有良好的耐受性，并且与有利于细胞毒性T淋巴细胞趋化和功能的干扰素刺激基因改变存在关联充分数据支持向2期临床研究推进 2期研究将评估载瘤αDC1疫苗配合顺铂/趋化因子调节性联合方案的免疫和临床疗效佛罗里达州奥卡拉, Jan. 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
January 24, 2022 08:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech、進行再発卵巣がんを対象とした腹腔内化学免疫療法の第1/2相治験で良好な結果が得られたことを発表

ケモカインを調節するIP化学免疫療法は、良好な忍容性を示し、インターフェロン刺激による遺伝子変化が細胞傷害性Tリンパ球の化学的集積と機能を促進することを実証強力なデータの結果、第2相治験への移行が可能となった第2相治験では、シスプラチン/ケモカイン調整療法と併用する腫瘍負荷αDC1ワクチンの免疫学的および臨床的有効性を評価するフロリダ州オカラ発, Jan. 24, 2022 ...
January 19, 2022 08:35 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference

OCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
December 09, 2021 07:20 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech’s Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza

OCALA, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific...